Adrenocortical Positron Emission Tomography/PET-CT Imaging

Area of Science:

• Radiology
• Nuclear Medicine
• Endocrinology

Background:

• Computed tomography (CT) and MR imaging are frequently used, leading to increased detection of asymptomatic adrenal masses.
• While CT and MR imaging are valuable, they can be insufficient for fully characterizing adrenal masses.
• Functional imaging modalities are necessary for further characterization when CT or MR imaging is inconclusive.

Purpose of the Study:

• To review the utility of various positron emission tomography (PET) radiopharmaceuticals for adrenocortical imaging.
• To highlight the role of PET in evaluating adrenal masses, particularly malignant conditions.

Main Methods:

• Discussion of various PET radiopharmaceuticals applicable to adrenocortical imaging.
• Review of existing literature on the use of FDG-PET in adrenal disease evaluation.

Main Results:

• 18-F-fluorodeoxyglucose (FDG)-PET has demonstrated effectiveness in evaluating malignant adrenal conditions.
• FDG-PET shows promising results for primary and metastatic adrenal disease with poor differentiation.

Conclusions:

• PET imaging, particularly with FDG, is a valuable tool for characterizing adrenal masses when conventional imaging is limited.
• Further research into various PET radiopharmaceuticals can enhance the diagnostic capabilities for adrenocortical lesions.